ENGINEERED NK CELLS
Provided herein, inter alia, are compositions including engineered NK cells and methods for preparing the same. The engineered NK cells provided herein include integrated nucleic acid sequences encoding Cas9 proteins (e.g. dCas9). The engineered NK cells are contemplated to be effective for treating and/or preventing cancer, particularly leukemia..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 18. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SWAMINATHAN SRIVIDYA [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-18, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
US2024016838 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019104537 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019104537 | ||
| 003 | DE-627 | ||
| 005 | 20240209083828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019104537 | ||
| 035 | |a (EPA)US2024016838 | ||
| 035 | |a (EPA)81383138 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SWAMINATHAN SRIVIDYA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ENGINEERED NK CELLS |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-18, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 | ||
| 520 | |a Provided herein, inter alia, are compositions including engineered NK cells and methods for preparing the same. The engineered NK cells provided herein include integrated nucleic acid sequences encoding Cas9 proteins (e.g. dCas9). The engineered NK cells are contemplated to be effective for treating and/or preventing cancer, particularly leukemia. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KUMAR ANIL |4 aut | |
| 700 | 0 | |a LEE SUNG JUNE |4 aut | |
| 700 | 0 | |a KHANI ADELEH TAGHI |4 aut | |
| 700 | 0 | |a CHEN CHUN-WEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 18. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:18 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81383138/publication/US2024016838A1?q=US2024016838 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2024 |b 18 |c 01 |
| 951 | |a AR | ||
| 952 | |j 2024 |b 18 |c 01 | ||